The therapeutic effects of MSc1 nanocomplex, synthesized by nanochelating technology, on experimental autoimmune encephalomyelitic C57/BL6 mice

Abstract

Purpose Currently approved therapies for multiple sclerosis (MS) at best only slow down its progression. Therefore, it is necessary to utilize novel technologies in order to synthesize smart multifunctional structures. In the present study, for the first time we evaluated the therapeutic potential of MSc1 nanocomplex, which was designed based on novel nanochelating technology. Materials and methods MSc1 cell-protection capacity, with and without iron bond, was evaluated against hydrogen peroxide (H 2 O 2 )-induced oxidative stress in cultured rat pheochromocytoma-12 cells. The ability of MSc1 to maintain iron bond at pH ranges of 1–7 was evaluated. Nanocomplex toxicity was examined by estimating the intraperitoneal median lethal dose (LD 50 ). Experimental autoimmune encephalomyelitic mice were injected with MSc1 14 days after disease induction, when the clinical symptoms appeared. The clinical score, body weight, and disease-induced mortality were monitored until day 54. In the end, after collecting blood samples for assessing hemoglobin and red blood cell count, the brains and livers of the mice were isolated for hematoxylin and eosin staining and analysis of iron content, respectively. Results The results showed that MSc1 prevented H 2 O 2 -induced cell death even after binding with iron, and it preserved its bond with iron constant at pH ranges 1–7. The nanocomplex intraperitoneal LD 50 was 1,776.59 mg/kg. MSc1 prompted therapeutic behavior and improved the disabling features of experimental autoimmune encephalomyelitis, which was confirmed by decreased clinical scores versus increased body mass and 100% survival probability. It did not cause any adverse effects on hemoglobin or red blood cell count. Histopathological studies showed no neural loss or lymphocyte infiltration in MSc1-treated mice, while the hepatic iron content was also normal. Conclusion These results demonstrate that MSc1 could be a promising beneficial novel agent and has the capacity to be evaluated in further studies.

BCc1, the novel antineoplastic nanocomplex, showed potent anticancer effects in vitro and in vivo

“…Also, BCc1 has had no adverse effects on hemoglobin and red blood cell levels. In addition, BCc1 like previous nanochelation-based structures, Msc1, Pac, Pas, and Paf) 10 , 11 has protected cells against H 2 O 2 -mediated oxidative stress, and also IR spectrum analysis has clearly demonstrated that BCc1 is an organic-hydrocarbon structure. These characters positively affect the nanocomplex biocompatibility.…”

“…In another study, MSc1 nanocomplex showed therapeutic behavior in an animal model of multiple sclerosis and prevented H 2 O 2 -induced cell death even after binding with iron in an in vitro model of oxidative stress. 10 Also Pac, Pas, and Paf nanocomplexes showed neuroprotective effects in the cellular model of Parkinson’s disease. 11 …”

Nanochelating based nanocomplex, GFc7, improves quality and quantity of human mesenchymal stem cells during in vitro expansion

“…Recently nanochelating technology [ 15 ] synthetized and introduced novel nano complexes based on a self- assembly method [ 16 , 17 , 33 ].…”

“…Hep-c improved cellular immune responses against hepatitis B vaccine [ 16 ]. MSc1 nano-complex showed therapeutic behavior in an animal model of multiple sclerosis [ 17 ] and neuroprotective effects of three different sizes of nanochelating based nano complexes in MPP(+) induced neurotoxicity [ 5 ] were recently reported.…”

<p>Effects of BCc1 nanoparticle and its mixture with doxorubicin on survival of murine 4T1 tumor model</p>

“…Nanochelating technology, a new branch of nanotechnology, has recently proved its noticeable impact in various sciences by synthesizing unique nanostructures 18. In our previous report, MSc1 nanocomplex, synthesized by nanochelating technology, exhibited therapeutic effects in an animal model of multiple sclerosis 19. Also, in an experimental model of Parkinson disease, Maghsoudi et al revealed neuroprotective effects of three nanochelating-based nanocomplexes 20.…”